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Abstract  
Objective: To analyze the cytotoxic effects of paclitaxel following introduction of the retroviral interferon- α (IFN- 
α) gene into epithelial ovarian cancer cells.  
Design: Experimental molecular study.  
Setting: University hospital research center. Sample: Epithelial ovarian cancer cell lines OV-2774 and SKOV3. 
Empty vector was used as control.  
Methods: The cytotoxic effects of paclitaxel on ovarian cancer cells were studied prior to and after transfection 
with the retrovirus-mediated inteferon- α gene. RT/PCR of the interferon gene, cell survival and cell death were 
analyzed to assess retroviral interferon- α gene expression after transfection.  
Results: Paclitaxel inhibited cell growth in a dose dependent manner with half maximal inhibitory concentration 
(IC50) of 7.5 ng/ml. Retroviral inteferon- α gene transfer-transduced cells potentiated paclitaxel response against 
both ovarian cancer cell lines by 68%.  
Conclusion:  Retrovirus-mediated IFN- α gene transfer enhanced paclitaxel cytotoxicity on ovarian cancer cells. 
Retroviral IFN- α gene transfer in combination with paclitaxel may have significant clinical utility for the 
treatment of epithelial ovarian cancers. 
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Introduction 
Ovarian cancer is estimated to have been responsible 
for slightly above half (52%) of gynecologic 
cancer-related deaths, according to the American 
Cancer Society for the year 2013 [1]. Epithelial 
ovarian cancer (EOC) is a specific type of ovarian 
cancer that develops in the epithelium and comprises 
90% of all ovarian cancers [2]. The vast majority of 
patients diagnosed and treated for EOC develop 
recurrences [3]. While various therapies have been 
established, the current standard of care for epithelial 
ovarian cancer following cytoreductive surgery is 
combination platinum and paclitaxel therapies, 
although rigorous research yielding more favorable 
long-lasting outcomes continues to develop, with 
plenty of room for improvements [4-6].  
Interferon-α (IFN-α) via retroviral gene transfer in 
vitro is a novel therapeutic approach receiving 
attention for its effects in a wide variety of cancers 
[7-10]. As epithelial ovarian cancer is confined within 
the peritoneal cavity, gene therapy using the delivery 
of IFN-α through viral vectors into the peritoneal 
cavity would appear to offer an alternative treatment 
option in treating ovarian cancers. In this study the 
anti-tumor activity of interferon-α over-expression 
using the retrovirus-mediated gene transfer was first 
assessed. Subsequently we evaluated the effects of 
interferon-α gene expression in combination with 
paclitaxel treatments on ovarian cancer cell lines 
OV2774 and SKOV3.  
Materials and methods 
Cell Lines, Paclitaxel Treatment   
Two human epithelial ovarian cancer cell lines, 
OV2774 and SKOV3, were obtained from MD 
Anderson Cancer Center, Houston, Texas (courtesy of 
Judith Wolf, M.D.). Cell cultures were grown at 37°C 
in 5% CO2 environment. OV2774 and SKOV3 were 
adjusted to 2x 106 cells/ml and were cultured in RPMI 
1640 medium supplemented by 10% fetal calf serum. 
The cell line was cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented by 10% 
heat-inactivated fetal bovine serum (FBS; Life 
Technologies, Rockville, Md.), 100 U/ml penicillin 
and streptomycin 100µg/ml. The drugs was kept at 
ambient temperature and made fresh in 0.9% NaCl at 
the time of use [11]. For cell culture experiments, 
dissolved agents were mixed with RPMI medium 
containing 10% FBS just before use. At the beginning 
of the treatment, the medium overlying the monolayers 
was removed, and the cells were covered with 2ml 
RPMI medium containing 10% FBS at pH 7.4 + 0.1 
and then treated with the drug for 4 h at 37°C. Based 
on what we previously published, paclitaxel were used 
at the concentrations of 2, 5, 7.5, 10, and 12 ng/ml [11]. 
At the end of the treatments, the cells were washed 
and assayed for viability. 
Retroviral vector and recombinant virus 
production  
The retrovirus vector encoding IFN-α was constructed 
in our laboratory as previously described [9]. Briefly, 
based on the backbones of retroviral vectors pLXSN 
and pLNCX (clontech, Palo Alto, CA) the 
replication-deficient retroviral vector (LSN-IFN-α) 
containing the human gene was constructed by 
inserting a 677-bp Xhol-Xhol human 5cDNA fragment 
from BMG neo IFN-α vector in the Xhol site of 
retroviral LXSN. PA 317 retroviral packaging cells (3 
x 105) were seeded into 60-mm dishes and incubated 
for 24h, then washed twice with serum reduced 
Opti-MEM (GIBCO-BRL). In the current study, 5 g of 
each of the retroviral vectors PA 317/LSN-IFN-α -H3, 
which produced the highest viral titer of 11x105 
cfu/ml, was incubated in 20 µl plasmid Lipofectamine 
reagent (Boehringer Mannheim, Mannheim Germany) 
for 30 min at ambient temperature, added to the 
culture dish cells, and incubated at 37°C for 5 h. After 
incubation, 3 ml DMEM containing 20% FBS was 
added to the culture dish, which was reincubated for 
18 h. The media were replaced by complete fresh 
media and reincubated for another 24 h. The cells were 
then passed 1 to 10 times into G418-containing 
medium (500µg/ml). After 14 days’ culture at 37°C, 
5% CO2, the transduced cells were subjected to a 
single cell cloning. For each isolated cells, the viral 
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titer was determined by real-time quantitative PCR as 
described [12]. Viral supernatants were collected, 
passed through 0.22m filters, and stored in aliquots at 
-80°C. 
Cytotoxicity and Cell Death Assay 
The cytotoxic effect of paclitaxel was studied both in 
cell cultures transfected with the interferon-α gene and 
those transfected with the empty vector. RT/PCR of 
the interferon gene, cell survival and cell death were 
analyzed to assess for interferon-α gene expression 
after infection [10, 11]. Cytotoxicity assays were 
performed with a combination of drug and the 
interferon-α gene. The combinations were analyzed 
according to the multiplication concept of drug 
interaction in both cultures [11, 13]. 
Statistical Analysis 
All values were from at least three independent 
experiments in triplicate and are expressed as the mean 
+ standard error of the mean. The probabilities of 
significant differences upon comparison of the groups 
were determined by two-tailed Student’s t-tests. 
Significance for the comparisons was inferred at 
p<0.05. 
Results 
We first examined the antiproliferative effects of 
paclitaxel on OV2774 and SKOV3 cell lines. The 
respective antiproliferative effect of paclitaxel is seen 
in Figure 1. Paclitaxel exerts a dose-dependent 
cytotoxic effect on ovarian cancer cell lines with 50% 
inhibition at a concentration of 7.5 ng/ml for 24-hour 
cultures (Figure 1).  
In the following set of experiments, we assessed the 
effect of retrovirus-mediated interferon gene construct 
on survival of OV2774 and SKOV3 cell lines. 
Supernatant of packing cell line PA317 cells at 
105-106 pfu/ml failed to achieve a high infection on 
the SKOV3 and OV2774 cell lines. Retroviral 
particles were centrifuged to acquire a higher 
concentration of 109-1010 pfu/ml (17). Infection of 
OV2774 and SKOV3 cells with the higher 
concentration achieved a higher infectivity and cell 
death. Using the ELISA kit to measure the secretion of 
Interferon-α, the maximal secretion was achieved after 
3-4 days of infection. As seen in Figure 2, the 
interferon protein produced by retroviral construct 
resulted in time-dependent OV2774 and SKOV3 cell 
death. Maximum cell death was achieved after 96 
hours of incubations. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Effect of different Paclitaxel concentrations on ovarian cancer cells OV2774 (opened column) and SKOV3 (solid 
column) survival. Ovarian cancer cell lines were cultured and treated with Paclitaxel and analyzed for cell death after 24 
hours of drug exposure as described in the materials and methods. There is a dose dependent cytotoxicity of Paclitaxel on 
both OV2774 and SKOV3 (P<0.001). 
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Figure 2 Effect of durations of IFN-α incubations on ovarian cancer cell OV2774 (opened column) and SKOV3 (solid 
column) (P<0.001) 
 
Next, we examined whether Interferon-α gene 
transfer may potentiate the cytotoxic effects of 
paclitaxel on OV2774 and SKOV3 cell lines. Cells 
were first infected with either retroviral empty vector 
or retrovirus mediated Interferon-α. After 12 hours of 
infection, paclitaxel was added for an additional 48 
hours and cell death was measured. We did not 
observe any cell death in control cells or cells infected 
with the empty viral vector. In our experiments, the 
retrovirus-mediated interferon gene potentiates the 
cytotoxicity of Paclitaxel on pretreated OV2774 and 
SKOV3 cells (Figure 3). In Figue 3, the cytotoxicity of 
Paclitaxel at 5ng/ml was enhanced by 68% when the 
ovarian cancer cells were pretreated with the 
retrovirus-mediated interferon gene. Our results show 
that expression of a functional interferon gene may 
enhance cell cytotoxicity when it is administered in 
combination with paclitaxel. 
 
 
 
 
 
 
 
 
 
 
Figure 3 Combinatory effect of Paclitaxel, and Paclitaxel after IFN-α gene transduction on Ovarian Cancer Cell OV2774 
(open column) and SKOV3 (solid column) (P<0.001) 
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Discussion 
Here we presented a unique approach using paclitaxel 
in combination with gene transfer as we demonstrate 
how the construction of a functional retroviral 
mediated interferon gene delivery resulted in 
enhancement of interferon secretion.  
Local expression of interferon in OV2774 and 
SKOV3 cell lines sensitizes the cells to paclitaxel. The 
combination of interferon transfer using retroviral 
vectors shows synergy in cell death, which may be of 
clinical significance. This may allow us to avoid the 
cytotoxicity in normal cells that is usually associated 
with using higher doses of paclitaxel alone. In 
previous retroviral studies IFN-α has been shown to 
have a short half-life of 3 hours, low detection rate 
near the site of tumors and toxic side effects, so both 
dosage and timing needed to be fine-tuned in order to 
yield higher response rates [14-16], which currently 
stands at a mere 30% over 5 years [5, 17]. 
The exact molecular mechanisms of the inhibitory 
effects of interferon are not fully understood; studies 
had supported host-mediated antitumor mechanisms 
induced by the local production of IFN-α. Other 
studies have shown immunomodulatory effects of 
IFN-α result in IFN-induced antitumor immunity [18]. 
Some data have demonstrated that IFN-α binds to the 
surface receptors and activates the interferon signaling 
cascade. It is suggested that part of this cascade 
involves proteins that act as tumor suppressors. 
Interferon is thought to activate receptors associated 
with tyrosine kinases. The best evidence of this model 
is the observation that interferon signaling is lost in 
cells deficient in a particular kinase, JAK 2. One 
substrate for the interferon activated tyrosine kinase is 
a multi-subunit transcription factor called ISGF-3. 
Upon tyrosine phosphorylation of multi-subunits, this 
factor assembles and moves from the cytoplasm to the 
nucleus, where it binds to specific sequences called 
interferon sequence response elements (ISRE). This 
results in the promotion of various interferon-α 
inducible genes initiating new gene transcription that 
may include tumor suppressor genes. The tumor 
suppression genes may well be activated in presence 
of paclitaxel. The revolutionary use of interferon gene 
transfer to assure cellular gene expression seems 
promising.  
The results of our study show that the 
retrovirus-mediated IFN-α gene transfer enhanced 
paclitaxel cytotoxicity on ovarian cancer cells. 
Retroviral interferon-α gene transfer in combination 
with paclitaxel may have significant clinical utility for 
the treatment of epithelial ovarian cancers. It is 
possible that present study demonstrating the potential 
benefits of gene transfer in cell cultures will lead to 
further development of molecular therapies and new 
treatments using existing chemotherapeutic drugs in 
the management of cancer. Future studies including 
gene expression and microarray expression of these 
genes will facilitate investigation into mechanism of 
dual treatment of chemotherapy and gene therapy of 
ovarian cancer. 
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